Lal S M, Trivedi H S, Ross G
Department of Internal Medicine, University of Missouri-Columbia, USA.
Int J Artif Organs. 1995 Jan;18(1):13-6.
Erythrocytosis is infrequently seen in renal transplant recipients. Both theophylline and angiotensin converting enzyme (ACE) inhibitors have been reported to decrease the elevated hematocrit (Hct) and hemoglobin (Hgb) levels. We studied the efficacy of the ACE inhibitors ramipril (n = 6) and enalapril (n = 1) in seven stable renal transplant recipients. Although the ACE inhibitors significantly reduced the elevated Hct and Hgb levels during the short and long term (Hct 53 +/- 1 vs 48.8 +/- 0.7%; Hgb 17.8 +/- 0.4 vs 16.7 +/- 0.3 vs 16.7 +/- 0.3 gm/dl, at 1 year), the clinical significance of these reductions remains unknown. During therapy there were no significant changes in the blood pressure, serum creatinine and potassium levels and the medications were well tolerated.
红细胞增多症在肾移植受者中并不常见。据报道，茶碱和血管紧张素转换酶（ACE）抑制剂均可降低升高的血细胞比容（Hct）和血红蛋白（Hgb）水平。我们研究了ACE抑制剂雷米普利（n = 6）和依那普利（n = 1）对7例稳定肾移植受者的疗效。尽管ACE抑制剂在短期和长期内均显著降低了升高的Hct和Hgb水平（1年后Hct为53±1 vs 48.8±0.7%；Hgb为17.8±0.4 vs 16.7±0.3 vs 16.7±0.3 g/dl），但这些降低的临床意义尚不清楚。治疗期间，血压、血清肌酐和钾水平无显著变化，且药物耐受性良好。
